Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity

References

• Kotsovilis S, Andreakos E. Therapeutic human monoclonal antibodies in inflammatory diseases. Methods Mol Biol. 2014;1060:37–59. PMID:24037835. doi:10.1007/978-1-62703-586-6_3.
   PubMedGoogle Scholar
• Fischer R, Kontermann RE, Maier O. Targeting sTNF/TNFR1 signaling as a new therapeutic strategy. Antibodies. 2015;4:48–70. doi:10.3390/antib4010048.
   Web of Science ®Google Scholar
• Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A. 1990;87:3127–3131. PMID:2158104. doi:10.1073/pnas.87.8.3127.
   PubMed Web of Science ®Google Scholar
• Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H, Lesslauer W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell. 1990b;61:351–359. PMID:215886. doi:10.1016/0092-8674(90)90815-V.
   PubMed Web of Science ®Google Scholar
• Loetscher H, Schlaeger EJ, Lahm HW, Pan YC, Lesslauer W, Brockhaus M. Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells. J Biol Chem. 1990a;265:20131–20138. PMID:2173696.
   PubMed Web of Science ®Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729–733. PMID:9034190. doi:10.1038/385729a0.
   PubMed Web of Science ®Google Scholar
• Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83:793–802. PMID:8521496. doi:10.1016/0092-8674(95)90192-2.
   PubMed Web of Science ®Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Diff. 2003;10:45–65. PMID:12655295. doi:10.1038/sj.cdd.4401189.
   PubMed Web of Science ®Google Scholar
• Williams SK, Maier O, Fischer R, Fairless R, Hochmeister S, Stojic A, Pick L, Haar D, Musiol S, Storch MK, et al. Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. PLoS One. 2014;9:e90117. PMID:24587232. doi:10.1371/journal.pone.0090117.
   PubMed Web of Science ®Google Scholar
• Winsauer C, Kruglov AA, Chashchina AA, Drutskaya MS, Nedospasov SA. Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice. Cytokine Growth Factor Rev. 2014;25:115–123. PMID:25305470. doi:10.1016/j.trsl.2014.09.006.
   PubMed Web of Science ®Google Scholar
• Probert L. TNF and its receptors in the CNS: the essential, the desirable and the deleterious effects. Neuroscience. 2015;302:2–22. PMID:26117714. doi:10.1016/j.neuroscience.2015.06.038.
   PubMed Web of Science ®Google Scholar
• Tseng WY, Huang YS, Lin HH, Luo SF, McCann F, McNamee K, Clanchy F, Williams R. TNFR signalling and its clinical implications. Cytokine. 2016. doi:10.1016/j.cyto.2016.08.027.
   PubMed Web of Science ®Google Scholar
• Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Cytokine. 2018;101:56–63. PMID:27567553. doi:10.1016/j.cyto.2016.08.014.
   PubMed Web of Science ®Google Scholar
• Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757–790. PMID:16979537. doi:10.1016/j.berh.2006.06.002.
   PubMed Web of Science ®Google Scholar
• Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res. 2015;165:270–282. doi:10.1016/j.trsl.2014.09.006.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12:49–62. PMID:26656660. doi:10.1038/nrrheum.2015.169.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Scheurich P, Pfizenmaier K. Antagonists of TNF action - clinical experience and new developments. Expert Opin Drug Discov. 2009;4:279–292. PMID:23489126. doi:10.1517/17460440902785167.
   PubMed Web of Science ®Google Scholar
• Van Hauwermeiren F, Vanderbroucke RE, Libert C. Treatment of TNF mediated diseases by selective inhibtion of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 2011;22:311–319. PMID:21962830. doi:10.1016/j.cytogfr.2011.09.004.
   PubMed Web of Science ®Google Scholar
• Fischer R, Maier O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxid Med Cell Longev. 2015;2015:610813. PMID:25834699. doi:10.1155/2015/610813.
   PubMed Web of Science ®Google Scholar
• Zettlitz KA, Lorenz V, Landauer K, Münkel S, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann R. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010;2:639–647. PMID:20935477. doi:10.4161/mabs.2.6.13583.
   PubMed Web of Science ®Google Scholar
• Richter F, Liebig T, Guenzi E, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE. Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity. PLoS One. 2013;8:e72156. PMID:23977237. doi:10.1371/journal.pone.0072156.
   PubMed Web of Science ®Google Scholar
• Dong Y, Fischer R, Naudé PJ, Maier O, Nyakas C, Duffey M, Van der Zee EA, Dekens D, Douwenga W, Herrmann A, et al. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration. Proc Natl Acad Sci U S A. 2016;113:12304–12309. PMID:27791020. doi:10.1073/pnas.1605195113.
   PubMed Web of Science ®Google Scholar
• Williams SK, Fairless R, Maier O, Liermann PC, Fischer R, Eisel OLM, Kontermann RE, Herrmann A, Weksler B, Romero IA, et al. Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Sci Rep. 2018;8:13628. doi:10.1038/s41598-018-31957-7.
   Google Scholar
• Kontermann RE, Münkel S, Neumeyer J, Müller D, Branschädel M, Scheurich P, Pfizenmaier K. A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action. J Immunother. 2008;31:225–234. PMID:18317365. doi:10.1097/CJI.0b013e31816a88f9.
   PubMed Web of Science ®Google Scholar
• Jakob CG, Edalji R, Judge RA, DiGiammarino E, Li Y, Gu J, Ghayur T. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule. MAbs. 2013;5:358–363. PMID:23549062. doi:10.4161/mabs.23977.
   PubMed Web of Science ®Google Scholar
• Gu J, Yang J, Chang Q, Liu Z, Ghayur T, Gu J. Identification of anti-EGFR and anti-ErbB3 Dual Variable Domains Immunoglobulin (DVD-Ig) proteins with unique activities. PLoS One. 2015;10:e0124135. PMID:25997020. doi:10.1371/journal.pone.0124135.
   PubMed Web of Science ®Google Scholar
• Ridgway JB, Presta LG, Carter P. “Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9:617–621. PMID:8844834. doi:10.1093/protein/9.7.617.
   PubMedGoogle Scholar
• Abhinandan KR, Martin AC. Analyzing the “degree of humanness” of antibody sequences. J Mol Biol. 2007;369:852–862. PMID:17442342. doi:10.1016/j.jmb.2007.02.100.
   PubMed Web of Science ®Google Scholar
• Seeliger D, Schulz P, Litzenburger T, Spitz J, Hoerer S, Blech M, Enenkel B, Studts JM, Garidel P, Karow AR. Boosting antibody developability through rational sequence optimization. MAbs. 2015;7:505–515. PMID:25759214. doi:10.1080/19420862.2015.1017695.
   PubMed Web of Science ®Google Scholar
• Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288:2351–2354. PMID:10875917. doi:10.1126/science.288.5475.2351.
   PubMed Web of Science ®Google Scholar
• Branschädel M, Aird A, Zappe A, Tietz C, Krippner-Heidenreich A, Scheurich P. Dual function of cysteine rich domain (CRD) 1 of TNF receptor type 1: conformational stabilization of CRD2 and control of receptor responsiveness. Cell Signal. 2010;22:404–414. PMID:19879354. doi:10.1016/j.cellsig.2009.10.011.
   PubMed Web of Science ®Google Scholar
• Chan FK. Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine. 2007;37:101–107. PMID:17449269. doi:10.1016/j.cyto.2007.03.005.
   PubMed Web of Science ®Google Scholar
• Bock K, Karlsson KA, Strömberg N, Teneberg S. Interaction of viruses, bacteria and bacterial toxins with host cell surface glycolipids. Aspects on receptor identification and dissection of binding epitopes. Adv Exp Med Biol. 1988;228:153–186. PMID:2459928.
   PubMedGoogle Scholar
• Root-Bernstein R. Rethinking molecular mimicry in rheumatic heart disease and autoimmune myocarditis: laminin, collagen IV, CAR, and B1AR as initial targets of disease. Front Pediatr. 2014;2:85. PMID:25191648. doi:10.3389/fped.2014.00085.
   PubMed Web of Science ®Google Scholar
• Rini JM, Schulze-Gahmen U, Wilson IA. Structural evidence for induced fit as a mechanism for antibody-antigen recognition. Science. 1992;255:959–965. PMID:1546293. doi:10.1126/science.1546293.
   PubMed Web of Science ®Google Scholar
• Wang W, Ye W, Yu Q, Jiang C, Zhang J, Luo R, Chen HF. Conformational selection and induced fit in specific antibody and antigen recognition: SPE7 as a case study. J Phys Chem B. 2013;117:4912–4923. PMID:23548180. doi:10.1021/jp4010967.
   PubMed Web of Science ®Google Scholar
• Lewis AK, Valley CC, Sachs JN. TNFR1 signaling is associated with backbone conformational changes of receptor dimers consistent with overactivation in the R92Q TRAPS mutant. Biochemistry. 2012;51:6545–6555. PMID:22799488. doi:10.1021/bi3006626.
   PubMed Web of Science ®Google Scholar
• Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 2000;50:184–195. PMID:10891884. doi:10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H.
   PubMed Web of Science ®Google Scholar
• Lundkvist Ryner M, Farrell RA, Fogdell-Hahn A. The case for measuring anti-drug antibodies in people with multiple sclerosis. Expert Rev Clin Immunol. 2014;10:697–699. PMID:24780058. doi:10.1586/1744666X.2014.914852.
   PubMed Web of Science ®Google Scholar
• Holland MC, Wurthner JU, Morley PJ, Birchler MA, Lambert J, Albayaty M, Serone AP, Wilson R, Chen Y, Forrest RM, et al. Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol. 2013;33:1192–1203. PMID:23832582. doi:10.1007/s10875-013-9915-0.
   PubMed Web of Science ®Google Scholar
• Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429–1435. PMID:23887439. doi:10.1007/s10067-013-2336-x.
   PubMed Web of Science ®Google Scholar
• Brocchini S, Godwin A, Balan S, Choi JW, Zloh M, Shaunak S. Disulfide bridge based PEGylation of proteins. Adv Drug Deliv Rev. 2008;60:3–12. PMID:17920720. doi:10.1016/j.addr.2007.06.014.
   PubMed Web of Science ®Google Scholar
• Khalili H, Godwin A, Choi JW, Lever R, Brocchini S. Comparative binding of disulfide-bridged PEG-Fabs. Bioconjug Chem. 2012;23:2262–2277. PMID:22994419. doi:10.1021/bc300372r.
   PubMed Web of Science ®Google Scholar
• Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;348:36–41. PMID:19567252. doi:10.1016/j.jim.2009.06.009.
   PubMed Web of Science ®Google Scholar
• Martin PL, Bugelski PJ. Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. Br J Pharmacol. 2012;166:806–822. PMID:22168335. doi:10.1111/j.1476-5381.2011.01812.x.
   PubMed Web of Science ®Google Scholar
• Powell MB, Mitchell D, Lederman J, Buckmeier J, Zamvil SS, Graham M, Ruddle NH, Steinman L. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol. 1990;2:539–544. PMID:1707660. doi:10.1093/intimm/2.6.539.
   PubMed Web of Science ®Google Scholar
• Suen WE, Bergman CM, Hjelmström P, Ruddle NH. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J Exp Med. 1997;186:1233–1240. PMID:9334362. doi:10.1084/jem.186.8.1233.
   PubMed Web of Science ®Google Scholar
• Chiang EY, Kolumam GA, Yu X, Francesco M, Ivelja S, Peng I, Gribling P, Shu J, Lee WP, Refino CJ, et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med. 2009;15:766–773. PMID:19561618. doi:10.1038/nm.1984.
   PubMed Web of Science ®Google Scholar
• Robak T1, Gladalska A, Stepień H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw. 1998;9:145–154. PMID:9681390.
   PubMed Web of Science ®Google Scholar
• O’Rourke KP, O’Donoghue G, Adams C, Mulcahy H, Molloy C, Silke C, Molloy M, Shanahan F, O’Gara F. High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations. Rheumatol Int. 2008;28:979–986. PMID:18379788. doi:10.1007/s00296-008-0574-z.
   PubMed Web of Science ®Google Scholar
• Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004;63:1344–1346. PMID:15033655. doi:10.1136/ard.2003.014878.
   PubMed Web of Science ®Google Scholar
• Ji H, Cao R, Yang Y, Zhang Y, Iwamoto H, Lim S, Nakamura M, Andersson P, Wang J, Sun Y, et al. TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat Commun. 2014;5:4944. PMID:25229256. doi:10.1038/ncomms5944.
   PubMed Web of Science ®Google Scholar
• Oshima H, Ishikawa T, Yoshida GJ, Naoi K, Maeda Y, Naka K, Ju X, Yamada Y, Minamoto T, Mukaida N, et al. TNF-α/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells. Oncogene. 2014;33:3820–3829. PMID:23975421. doi:10.1038/onc.2013.356.
   PubMed Web of Science ®Google Scholar
• Lou J, Marks JD. Affinity maturation by chain shuffling and site directed mutagenesis. In: Kontermann RE, Dübel S, editors. Antibody engineering. Berlin: Springer; 2010. p. 199. doi:10.1007/978-3-662-04605-0_9.
   Google Scholar
• Thie H. Affinity maturation by random mutagenesis and phage display. In: Kontermann RE, Dübel S, editors. Antibody engineering. Berlin: Springer; 2010. p. 199. doi:10.1007/978-3-662-04605-0_9.
   Google Scholar
• Kontermann RE. Immunotube selections. In: Kontermann RE, Dübel S, editors. Antibody engineering. Berlin: Springer; 2010. p. 199. doi:10.1007/978-3-662-04605-0_9.
   Google Scholar